StockNews.com Begins Coverage on Pro-Dex (NASDAQ:PDEX)

StockNews.com started coverage on shares of Pro-Dex (NASDAQ:PDEXGet Rating) in a research note issued on Sunday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

Separately, Ascendiant Capital Markets decreased their price objective on Pro-Dex to $30.00 and set a “na” rating for the company in a research note on Monday, May 16th.

NASDAQ PDEX opened at $15.51 on Friday. Pro-Dex has a one year low of $12.40 and a one year high of $35.68. The company has a market cap of $56.13 million, a P/E ratio of 17.83 and a beta of 1.12. The business has a fifty day moving average price of $15.54 and a 200 day moving average price of $19.57. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.10 and a current ratio of 3.64.

Institutional investors have recently bought and sold shares of the stock. LSV Asset Management boosted its stake in shares of Pro-Dex by 13.9% in the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock valued at $588,000 after buying an additional 4,346 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Pro-Dex by 59.2% in the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock valued at $345,000 after buying an additional 7,762 shares in the last quarter. Morgan Stanley boosted its position in Pro-Dex by 298.8% during the third quarter. Morgan Stanley now owns 10,456 shares of the medical instruments supplier’s stock worth $268,000 after purchasing an additional 7,834 shares in the last quarter. State Street Corp boosted its position in Pro-Dex by 5.8% during the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier’s stock worth $197,000 after purchasing an additional 650 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Pro-Dex by 11.2% during the second quarter. Wells Fargo & Company MN now owns 3,283 shares of the medical instruments supplier’s stock worth $101,000 after purchasing an additional 331 shares in the last quarter. Hedge funds and other institutional investors own 16.73% of the company’s stock.

About Pro-Dex (Get Rating)

Pro-Dex, Inc designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

See Also

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.